FDA-EMA work­shop dis­cuss­es qual­i­ty chal­lenges for PRIME, break­through ther­a­pies

Last No­vem­ber, of­fi­cials from the EMA and FDA met with in­dus­try rep­re­sen­ta­tives in Lon­don to dis­cuss the var­i­ous qual­i­ty chal­lenges that arise when the de­vel­op­ment of in­ves­ti­ga­tion­al prod­ucts is ac­cel­er­at­ed.

The EMA’s launch of its pri­or­i­ty med­i­cines (PRIME) scheme and the FDA’s break­through ther­a­py des­ig­na­tion have en­abled com­pa­nies to speed cer­tain treat­ments to mar­ket, al­though there have been dif­fi­cul­ties in iden­ti­fy­ing pos­si­ble sci­en­tif­ic and reg­u­la­to­ry ap­proach­es to fa­cil­i­tate the type of ro­bust qual­i­ty da­ta pack­ages nec­es­sary to en­sure that pa­tient safe­ty and prod­uct qual­i­ty and ef­fi­ca­cy are not com­pro­mised, ac­cord­ing to a re­port re­leased Wednes­day on the work­shop.

Ramesh Sood

In ad­di­tion to the fo­cus on ear­ly ac­cess ap­proach­es, the work­shop dis­cussed process val­i­da­tion, con­trol strate­gies, good man­u­fac­tur­ing prac­tice (GMP) com­pli­ance, com­pa­ra­bil­i­ty, sta­bil­i­ty and reg­u­la­to­ry tools.

Ramesh Sood, se­nior sci­en­tif­ic ad­vi­sor at the FDA’s Of­fice of New Drugs, dis­cussed the agency’s break­through pro­gram, not­ing the chal­lenges faced by ap­pli­cants col­lect­ing the nec­es­sary man­u­fac­tur­ing da­ta and pro­vid­ing an ad­e­quate man­u­fac­tur­ing con­trol strat­e­gy.

“It be­comes im­por­tant for the Agency re­view­ers to do a risk-ben­e­fit as­sess­ment re­gard­ing [the] risk of less man­u­fac­tur­ing in­for­ma­tion ver­sus pa­tient ben­e­fit,” the work­shop re­port says of Sood’s pre­sen­ta­tion. “This re­quires in­no­v­a­tive risk-mit­i­ga­tion strate­gies to en­sure prod­uct qual­i­ty and re­duce the qual­i­ty-re­lat­ed prod­uct risk to an ac­cept­able lev­el.”

Veroni­ka Jek­er­le

Veroni­ka Jek­er­le of the EMA’s qual­i­ty of­fice al­so dis­cussed the sci­en­tif­ic chal­lenges for PRIME can­di­dates, which in­clude ab­bre­vi­at­ed time­lines that add con­straints to set­ting up com­mer­cial man­u­fac­tur­ing sites.

“An analy­sis ex­am­in­ing sci­en­tif­ic is­sues most com­mon­ly iden­ti­fied by PRIME ap­pli­cants (as in­di­cat­ed by SA [sci­en­tif­ic ad­vice] re­quests) re­vealed the fol­low­ing ar­eas as the most crit­i­cal: start­ing ma­te­ri­als, com­pa­ra­bil­i­ty, process val­i­da­tion, an­a­lyt­i­cal con­trol strat­e­gy, spec­i­fi­ca­tions and sta­bil­i­ty,” the re­port says.

Stu­art Finnie, di­rec­tor of reg­u­la­to­ry CMC at As­traZeneca, al­so pre­sent­ed on a small mol­e­cule prod­uct that earned the FDA’s break­through des­ig­na­tion but ran in­to process val­i­da­tion prob­lems that meant sup­plies of the drug would come four months af­ter ap­proval.

As­traZeneca ap­proached the FDA and dis­cussed de­cou­pling the val­i­da­tion of drug sub­stance and drug prod­uct, and dis­cussed plans to use drug sub­stance man­u­fac­tured in the clin­i­cal fa­cil­i­ty to sup­ply drug prod­uct val­i­da­tion.

“Three key el­e­ments lead to the suc­cess of this pro­pos­al,” the re­port says of the As­traZeneca work. “First­ly, the ap­pli­cant pro­vid­ed the Agency with sig­nif­i­cant ev­i­dence of sim­i­lar­i­ty in terms of qual­i­ty, man­u­fac­tur­ing process and qual­i­ty sys­tem be­tween the clin­i­cal cam­paigns and the pro­posed com­mer­cial cam­paign. Sec­ond­ly, dur­ing the site in­spec­tion there was open and close en­gage­ment be­tween the in­spec­tors, re­view­ers, sub­ject mat­ter ex­perts and qual­i­ty de­part­ments en­sur­ing that ques­tions raised were an­swered swift­ly lead­ing to a bal­anced and aligned view on risk as­sess­ment. Fi­nal­ly, and most im­por­tant­ly, it was clear that through­out the in­ter­ac­tions all par­ties were fo­cused on en­sur­ing sup­ply to the pa­tient.”

Oth­er in­dus­try pre­sen­ta­tions in­volved rep­re­sen­ta­tives from Pfiz­er, Am­gen, Cel­gene, MSD (known as Mer­ck in the US), Bio­gen and sev­er­al vac­cine man­u­fac­tur­ers, among oth­ers.

As far as fu­ture joint EMA-FDA ac­tions, the re­port points to the use of mod­els for sta­bil­i­ty and shelf life de­ter­mi­na­tions, in­no­v­a­tive process val­i­da­tion ap­proach­es and al­low­ing launch­es from clin­i­cal man­u­fac­tur­ing sites.

Ned Sharp­less NIH

“In ad­di­tion, the or­ga­niz­ing com­mit­tee pro­pos­es to de­vel­op a ‘Tool­box- guid­ance’ for PRIME prod­ucts, which shall sum­marise the iden­ti­fied sci­en­tif­ic el­e­ments/reg­u­la­to­ry tools that are al­ready avail­able in the EU to ad­dress some of the chal­lenges faced dur­ing the de­vel­op­ment of prod­ucts un­der PRIME and gen­er­a­tion of ro­bust qual­i­ty pack­ages for MAA [mar­ket­ing au­tho­riza­tion ap­pli­ca­tion] re­view,” the re­port says.

Act­ing FDA Com­mis­sion­er Ned Sharp­less added in a state­ment: “We will con­tin­ue to work with our EMA col­leagues and in­dus­try to dis­cuss ways to ad­dress qual­i­ty chal­lenges as­so­ci­at­ed with ex­pe­dit­ed de­vel­op­ment pro­grams to help en­sure pa­tients re­ceive safe, ef­fec­tive drugs.”

Work­shop Re­port

RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.


Zachary Brennan

managing editor, RAPS

Lessons for biotech and phar­ma from a doc­tor who chased his own cure

After being struck by a rare disease as a healthy third year medical student, David Fajgenbaum began an arduous journey chasing his own cure. Amidst the hustle of this year’s JP Morgan conference, the digital trials platform Medable partnered with Endpoints Studio to share Dr. Fajgenbaum’s story with the drug development industry.

What follows is an edited transcript of the conversation between Medable CEO Dr. Michelle Longmire and Dr. Fajgenbaum, and it is full of lessons for biotech executives charged with bringing the next generation of medicines to patients.

James Collins, Broad Institute via Youtube

UP­DAT­ED: A space odyssey for new an­tibi­otics: MIT's ma­chine learn­ing ap­proach

Drug development is complex, expensive and comes with lousy odds of success — but in most cases, if you make it across the finish line brandishing a product with an edge (and play your cards right) it can be a lucrative endeavor.

As it stands, the antibiotic market is cursed — it harbors the stink of multiple bankruptcies, a dearth of innovation, and is consequently barely whetting the voracious appetites of big pharma or venture capitalists. Enter artificial intelligence — the biopharma industry’s cure-all for the pesky process of making a therapeutic, including data mining, drug discovery, optimal drug delivery, and addressable patient population.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 72,800+ biopharma pros reading Endpoints daily — and it's free.

Gilead los­es two more patent chal­lenges on HIV pill, set­ting up court­room fight in Delaware

Gilead sustained two more losses in their efforts to rid themselves of an activist-backed patent lawsuit from the US government over a best-selling HIV pill.

Urged on by activists seeking to divert a portion of Gilead’s revenue to clinics and prevention programs, the Department of Health and Human Services made a claim to some of the patents for the best-selling HIV prevention drug, Truvada, also known as PrEP. Gilead responded by arguing in court that HHS’s patents were invalid.

Today, the US Patent and Trademark Office ruled that Gilead was likely to lose the last two of those challenges as well. The USPTO ruled against Gilead on the first two patents earlier this month.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 72,800+ biopharma pros reading Endpoints daily — and it's free.

Jim Scholefield via PR Newswire

Mer­ck los­es its chief dig­i­tal of­fi­cer, spot­light­ing tal­ent hunt for the hottest ti­tle in Big Phar­ma

Over the last few years we’ve seen the chief digital officer title become one of the hottest commodities in Big Pharma as global organizations hunt the best talent to sharpen the cutting edge of their tech platforms.

But Merck just discovered how hard it may be to keep them focused on pharma.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 72,800+ biopharma pros reading Endpoints daily — and it's free.

Kathy High (file photo)

Gene ther­a­py pi­o­neer Kathy High has left Spark af­ter com­plet­ing $4.3B union with Roche

Kathy High dedicated the past seven years of her life shepherding experimental gene therapies she’s developed at Children’s Hospital of Philadelphia toward the market as president and head of R&D at Spark Therapeutics. Now that the biotech startup is fully absorbed into Roche — with an FDA approval, a $4.3 billion buyout and a promising hemophilia program to boast — she’s ready to move on.

Roche confirmed her departure with Endpoints News and noted “she will take some well-deserved time off and then will begin a new chapter in a sabbatical at a university.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 72,800+ biopharma pros reading Endpoints daily — and it's free.

Bank­rupt an­tibi­otics mak­er Ar­a­digm turns to old part­ner/in­vestor for fi­nal $3M fire sale

Grifols once paid Aradigm $26 million for a stake in its inhaled antibiotics. But with Aradigm now in bankruptcy, the Spanish drugmaker is dishing out a final $3.2 million to buy it all.

The fire sale — which comes one year after Aradigm filed for Chapter 11 following a regulatory trifecta for disaster — will see Grifols obtain assets and IP to Apulmiq (formerly Pulmaquin and Linhaliq in Europe), Lipoquin and free ciprofloxacin. In addition to waiving its claims in the bankruptcy case, Grifols also agreed to milestone payments up to $3 million more upon any regulatory approvals.

Tal Zaks (Moderna via YouTube)

For two decades, a new vac­cine tech­nol­o­gy has been slow­ly ap­proach­ing prime time. Now, can it stop a pan­dem­ic?

Two months before the outbreak, Moderna CMO Tal Zaks traveled from Cambridge, MA to Washington DC to meet with Anthony Fauci and the leaders of the National Institutes of Health.

For two years, Moderna had worked closely with NIH researchers to build a new kind of vaccine for MERS, one of the deadliest new viruses to emerge in the 21st century. The program was one test for a new technology designed to be faster, cheaper and more precise than the ways vaccines had been made for over a century. They had gathered evidence the technology could work in principle, and Fauci, the longtime head of the National Institute of Allergy and Infectious Diseases and a longtime advocate for better epidemic preparedness, wanted to see if it, along with a couple of other approaches, could work in a worst-case scenario: A pandemic.

“[We were] trying to find a test case for how to demonstrate if our technology could rapidly prepare,” Zaks told Endpoints News.

Zaks and Fauci, of course, wouldn’t have to wait to develop a new test. By year’s end, an outbreak in China would short circuit the need for one and throw them into 24/7 work on a real-world emergency. They also weren’t the only ones with new technology who saw a chance to help in a crisis.

An ocean away, Lidia Oostvogels was still on vacation and relaxing at her mother’s house in Belgium when her Facebook started changing. It was days after Christmas and on most people’s feeds, the news that China had reported a novel virus to the World Health Organization blurred into the stream of holiday sweaters and fir trees. But on Oostvogels’s feed, full of vaccine researchers and virus experts, speculation boiled: There was a virus in China, something contained to the country, but “exotic,” “weird,” and maybe having to do with animals. Maybe a coronavirus.

Lidia Oostvogels

“I was immediately thinking like, ‘Hey, this is something that if needed, we can play a role,'” Oostvogels told Endpoints.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 72,800+ biopharma pros reading Endpoints daily — and it's free.

DB­V's peanut pre­ven­tion patch ap­proach­es key stage of ap­proval process

Almost a year and a half after DBV Technologies pulled its peanut allergy immunotherapy patch from FDA review, the biotech will get their day in court. The FDA has scheduled an advisory committee hearing for May 15.

In the two-horse race to develop the first immunotherapy for peanut allergy, DBV had the early lead, filing an NDA for their patch in 2018. But on December 20 of that year, the company withdrew their application after, they said, meeting with regulators and determining they had not submitted “sufficient detail regarding data on manufacturing procedures and quality controls.” Aimmune filed their BLA 3 days later and won approval as the first immunotherapy for peanuts this month.

An­to­nio Gual­ber­to starts post-Ku­ra ca­reer at Ei­sai sub­sidiary H3; eF­FEC­TOR co-founder Siegfried Re­ich jumps to Turn­ing Point

→ Days after Kura Oncology announced the departure of co-founder Antonio Gualberto, we finally know where he wound up. Eisai subsidiary H3 Biomedicine has recruited him as CMO to finding the right patients to its four clinical-stage small molecule assets hitting genomic drivers of cancer.

“Challenges of these and many other precision medicine approaches are on one hand technical — a need for robust and precise diagnostics — and on the other hand derived by the challenge to alter standard clinical practice in settings where patient screening, e.g. by tumor DNA sequencing, is not standard practice,” he wrote to Endpoints News on his way back to Boston from Eisai’s Tokyo offices. “Only compelling clinical activity can drive clinicians and pathologists to modify standard clinical practice.”